Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange Other stock markets 11:30:00 31/05/2024 am IST			5-day change	1st Jan Change
4,173 ^JPY	+1.88%		+0.94%	+2.94%

02:00pm	GSK blood cancer drug nearly halves risk of death in late-stage trial	RE
31/05	Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	31/05	BU
Takeda Pharmaceutical : Other items which are provided electronically	29/05	PU
TAKEDA PHARMACEUTICAL : Form 6-K	21/05	PU
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	16/05	AQ
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting	14/05	BU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease	13/05	BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	10/05	AQ
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement	10/05	AQ
Takeda Pharmaceutical : FINANCIAL APPENDIX - Form 6-K	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Presentation	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Financial Report	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Highlights Infographic	09/05	PU
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion	09/05	BU
Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	09/05	EQ
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	29/04	AQ
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26/04	BU
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04	AQ
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9	19/04	AQ
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease	19/04	BU
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food	08/04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Press Releases

Filters